LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor

被引:67
|
作者
Wang, Y. [1 ]
Poulin, E. J. [2 ]
Coffey, R. J. [1 ,3 ]
机构
[1] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37232 USA
[3] Dept Vet Affairs Med Ctr, Nashville, TN 37232 USA
关键词
LRIG1; tumour suppressor; EGFR signalling; stem cell; LEUCINE-RICH REPEATS; IMMUNOHISTOCHEMICAL ANALYSIS; GENE-EXPRESSION; RECEPTOR; CANCER; GROWTH; PROLIFERATION; PROGNOSIS; CARCINOMA; SURVIVAL;
D O I
10.1038/bjc.2013.138
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In baseball parlance, a triple threat is a person who can run, hit and throw with aplomb. Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) is a cell surface protein that antagonises ERBB receptor signalling by downregulating receptor levels. Over 10 years ago, Hedman et al postulated that LRIG1 might be a tumour suppressor. Recently, Powell et al provided in vivo evidence substantiating that claim by demonstrating that Lrig1 loss in mice leads to spontaneously arising, highly penetrant intestinal adenomas. Interestingly, Lrig1 also marks stem cells in the gut, suggesting a potential role for Lrig1 in maintaining intestinal epithelial homeostasis. In this review, we will discuss the ability of LRIG1 to act as a triple threat: pan-ERBB negative regulator, intestinal stem cell marker and tumour suppressor. We will summarise studies of LRIG1 expression in human cancers and discuss possible related roles for LRIG2 and LRIG3.
引用
收藏
页码:1765 / 1770
页数:6
相关论文
共 50 条
  • [21] LRIG1 is a positive prognostic marker in Merkel cell carcinoma and Merkel cell carcinoma expresses epithelial stem cell markers
    Benjamin Sundqvist
    Harri Sihto
    Maria von Willebrand
    Tom Böhling
    Virve Koljonen
    Virchows Archiv, 2021, 479 : 1197 - 1207
  • [22] The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases (vol 279, 47050, 2004)
    Laederich, MB
    Funes-Duran, M
    Yen, L
    Ingalla, E
    Wu, XL
    Carraway, KL
    Sweeney, C
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (50)
  • [23] EXPRESSION OF LRIG1, A NEGATIVE REGULATOR OF EGFR, IS DYNAMICALLY ALTERED IN DIFFERENT STAGES OF GASTRIC CARCINOGENESIS
    Kim, Hyunji
    Yu, Sungsook
    Cho, Yejin
    Coffey, Robert J.
    Goldenring, James R.
    Nam, Ki Taek
    Yang, Mijeong
    Lee, Keunwook
    Jeong, Sang-Ho
    Lim, Kyung-Min
    GASTROENTEROLOGY, 2018, 154 (06) : S330 - S330
  • [24] Single-cell expression profiling of human epidermal stem and transit-amplifying cells: Lrig1 is a regulator of stem cell quiescence
    Jensen, Kim B.
    Watt, Fiona M.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (32) : 11958 - 11963
  • [25] Local delivery of the soluble form of the tumor suppressor and stem cell regulator LRIG1 potently inhibits in vivo growth of glioblastomas with either wildtype or mutant EGFR expression
    Niclou, S. P.
    Johansson, M.
    Tiemann, K.
    Oudin, A.
    Hedman, H.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S777 - S777
  • [26] LRIG1 is a novel negative regulator of the Met receptor and opposes met and Her2 synergy
    Shattuck, David L.
    Miller, Jamie K.
    Laederich, Melanie
    Funes, Melanie
    Petersen, Heidi
    Carraway, Kermit L., III
    Sweeney, Colleen
    MOLECULAR AND CELLULAR BIOLOGY, 2007, 27 (05) : 1934 - 1946
  • [27] Expression of LRIG1, a Negative Regulator of EGFR, Is Dynamically Altered during Different Stages of Gastric Carcinogenesis
    Yu, Sungsook
    Yang, Mijeong
    Lim, Kyung-Min
    Cho, Yejin
    Kim, Hyunji
    Lee, Keunwook
    Jeong, Sang-Ho
    Coffey, Robert J.
    Goldenring, James R.
    Nam, Ki Taek
    AMERICAN JOURNAL OF PATHOLOGY, 2018, 188 (12): : 2912 - 2923
  • [28] Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer
    Umeh-Garcia, Maxine
    O'Geen, Henriette
    Simion, Catalina
    Gephart, Melanie Hayden
    Segal, David J.
    Sweeney, Colleen A.
    BRITISH JOURNAL OF CANCER, 2022, 127 (03) : 436 - 448
  • [29] Aberrant promoter methylation contributes to LRIG1 silencing in basal/triple-negative breast cancer
    Maxine Umeh-Garcia
    Henriette O’Geen
    Catalina Simion
    Melanie Hayden Gephart
    David J. Segal
    Colleen A. Sweeney
    British Journal of Cancer, 2022, 127 : 436 - 448
  • [30] MicroRNA Expression Profiling of Normal and Malignant Human Colonic Stem Cells Identifies miRNA92a as a Regulator of the LRIG1 Stem Cell Gene
    Viswanathan, Vignesh
    Opdenaker, Lynn
    Modarai, Shirin
    Fields, Jeremy Z.
    Gonye, Gregory
    Boman, Bruce M.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (08)